Inscripta is developing the world’s first benchtop platform for scalable digital genome engineering. The company’s advanced CRISPR-based platform, consisting of an instrument, consumables, software, and assays, offers a fully automated workflow that enables massively parallel, trackable editing of single cells at an unprecedented scale.

Inscripta’s goal is to empower scientists whose gene editing research is stifled by current technical and licensing limitations. By providing this unique platform and engaging in collaborative business practices, such as making its MAD7^™ CRISPR nuclease free for research and development purposes, the company enables scientists to realize a new era of biological discovery.

Inscripta merged with Manus in April 2025 to establish a unique end-to-end platform for scalable development, biomanufacturing, and commercialization of bioalternative products.